Strategy & Optimization Director, (Multi-Specialty)

McKesson•Irving, TX

13d

About The Position

McKesson is an impact-driven, Fortune 10 company that touches virtually every aspect of healthcare. We are known for delivering insights, products, and services that make quality care more accessible and affordable. Here, we focus on the health, happiness, and well-being of you and those we serve – we care. What you do at McKesson matters. We foster a culture where you can grow, make an impact, and are empowered to bring new ideas. Together, we thrive as we shape the future of health for patients, our communities, and our people. If you want to be part of tomorrow’s health today, we want to hear from you. The Strategy & Optimization Director, Onmark MSPL, will lead initiatives that optimize performance and drive long-term growth across member practices, aggregator groups, such as Onmark Vision, and other GPO programs and initiatives. This role serves as a strategic liaison between provider organizations and biopharma partners, influencing contract strategies and delivering enhanced economics for member providers. The Strategy & Optimization Director will play a critical role in shaping aggregate contracting strategies, forecasting multi-year performance, and guiding strategic planning sessions for providers. This position also leads large, complex initiatives with innovative thinking that drive industry change and create significant economic impact, positioning Onmark as a leader in strategic contracting and provider engagement.

Requirements

Degree or equivalent and typically requires 7+ years of relevant experience.
Bachelor’s degree required (Business, Economics, Finance, or related field); MBA or advanced degree preferred.
7+ years of relevant healthcare experience, including strategic planning, financial analysis, and provider engagement.
7+ years in leadership roles with proven success in strategy execution and business growth.
Extensive experience in financial forecasting and market analysis.
Strong understanding of biopharma economics, aggregate contracting strategies, and disease state dynamics.
Advanced Excel and PowerPoint skills; ability to build compelling business cases and presentations.
Exceptional relationship management and communication skills; ability to influence at all levels.
Proven ability to lead strategic initiatives with significant impact on provider economics and organizational growth.

Nice To Haves

Previous GPO experience and biopharma engagement strongly preferred.

Responsibilities

Develop and execute short- and long-term strategic plans for aggregate contracts across multiple GPO programs.
Lead strategic planning sessions with providers to align practice goals with economic success and contract optimization.
Perform competitive analysis, track industry trends, and maintain extensive knowledge of market conditions.
Act as a strategic liaison with biopharma partners, collaborating with Business Development Directors to craft contracts based on provider feedback.
Provide economic comparisons and optimization strategies to enhance contract performance and profitability.
Engage with clinical and contract committee leadership to influence strategic decisions.
Lead forecasting for multi-year aggregate contract performance.
Deliver financial modeling and scenario planning to identify opportunities for improved economics.
Incorporate market trend analysis and disease state expertise (retina, rheumatology, neurology, ambulatory infusion centers) into recommendations.
Drive innovation of new projects and initiatives that lead industry change and deliver measurable economic impact.
Lead complex, cross-functional projects to improve value, streamline efficiencies, and enhance customer experience.
Serve as a trusted advisor and fiduciary to C-suite executives, biopharma partners, and provider leadership.
Present regularly to GPO leadership on strategic initiatives, contract performance, and market dynamics.
Drive cross-functional collaboration with Sales, Clinical Specialists, and internal teams to execute aggregate buy-in strategies.